Latest research on Cisplatin

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Latest findings

In this study therefore, we hypothesized that noscapine, orally administered via a mannosylated HPMC-coated self-emulsifying carrier will be bioavailable and enhance tumor responsiveness to Cisplatin. [source, 2016]
To test our hypothesis, we utilized a spray-dried mannosamine-HPMC matrix over a noscapine-loaded self-microemulsifying drug delivery system (SMEDD) to evaluate (a) the release rate, (b) transport across a colon cancer carcinoma cell (Caco-2) model, (c) pharmacokinetic plasma exposure in orally administered rats, and (d) tumor response to a combination regimen of noscapine and Cisplatin in an orthotopic mouse model of chemorefractory H1650-induced non-small cell lung cancer (NSCLC). [source, 2016]
Treatment was carried out with different concentrations of Cisplatin and/or noscapine and incubated for 72 hr. [source, 2016]
Cell viability studies for combinations of noscapine and Cisplatin were done by varying the concentrations of Cisplatin with fixed concentrations (5 and 20 μM) of noscapine and incubating for 72 hr post-treatment. [source, 2016]
Similarly, the effect of 20 μM noscapine base in Nos_SESD, Mann-Nos_SESD, and their combination with different concentration of Cisplatin on the cell 72-hr viability of H1650 SP cells was investigated. [source, 2016]
The 20 μM equivalent weight of Nos_SESD (26.70 μg) and Mann-Nos_SESD (25.80 μg) per ml of solvent (RPMI 1640) media were added to H1650 SP cells treated with and without different concentrations Cisplatin to obtain a total noscapine base concentration of 20 μM in 200 μL final volume. [source, 2016]
Animals were randomized into 7 groups (n = 4) of (i) untreated, (ii) Cisplatin, (Cis) (2 mg/kg/biweekly I.V.,), (iii) Nos_SESDs (300 mg/kg/day), (iv) Mann-Nos_SESDs (150 mg/kg/day), (v) Mann-Nos_SESDs (300 mg/kg/day), (vi) Mann-Nos_SESDs (150 mg/kg/day) + Cis (2 mg/kg/wk I.V.), and (vii) Mann-Nos_SESDs (300 mg/kg/day) + Cis (2 mg/kg/wk, I.V. [source, 2016]
To establish the resistance potential of H1650 SP cells used in our model, we compared the abilities of untreated H1650 SP and H1650 MP cells to form spheroids in matrix-coated Lipidure® plates as well as its comparative response to Cisplatin (Cis) and Noscapine (Nos) (Fig 4). [source, 2016]
Noscapine (Nos) and Cisplatin (Cis) each exhibited dose-dependent inhibition of H460 and H1650 MP 72 hr cell viabilities (Fig 4b and 4c). [source, 2016]
This was consistent with the decreased susceptibility of H1650 SP cells (Fig 4d) to Cisplatin (Cis) or Noscapine (Nos) compared to H1650 MP and the positive control H460 cells (Fig 4b and 4c). [source, 2016]